CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
ATE121102T1
(de)
|
1990-04-20 |
1995-04-15 |
Hisayuki Matsuo |
Neue im schwein vorkommende physiologisch aktive peptide.
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド(cnp―53)
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタcnp遺伝子及び前駆体蛋白
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド(ニワトリcnp)
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド(カエルcnp)
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットCNPcDNA及び前駆体蛋白
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトcnp遺伝子及び前駆体蛋白
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Cnp類似体ペプチド
|
CA2102808A1
(en)
|
1991-05-10 |
1992-11-11 |
Hanne Bentz |
Targeted delivery of bone growth factors
|
WO1994020534A1
(en)
|
1993-03-03 |
1994-09-15 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
WO1995005455A1
(en)
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
ES2194895T3
(es)
|
1993-11-12 |
2003-12-01 |
Genentech Inc |
Peptidos natriureticas atriales especifico de un receptor.
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
AU2671795A
(en)
|
1994-06-02 |
1996-01-04 |
Boehringer Mannheim Gmbh |
Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
CA2269656A1
(en)
|
1996-10-22 |
1998-04-30 |
Genentech, Inc. |
Receptor specific brain natriuretic peptide (bnp)
|
WO1998035703A2
(en)
|
1997-02-14 |
1998-08-20 |
The Salk Institute For Biological Studies |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
JP4394279B2
(ja)
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
|
CA2245903A1
(en)
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
CA2262056A1
(en)
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
JP2002542304A
(ja)
|
1999-04-28 |
2002-12-10 |
ベクトレイムド インコーポレイテッド |
酵素的に活性化された重合薬物接合体
|
JP2000327583A
(ja)
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
WO2000069900A2
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
AU1920201A
(en)
|
1999-11-16 |
2001-05-30 |
Genzyme Corporation |
Improved regulatory elements for delivery to the liver
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
AU2277201A
(en)
|
1999-12-17 |
2001-06-25 |
Ariad Pharmaceuticals, Inc. |
Novel purines
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
AU2001250221B2
(en)
|
2000-04-26 |
2006-07-06 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
ATE341631T1
(de)
|
2000-08-23 |
2006-10-15 |
Enobia Pharma Inc |
Methode und zusammensetzung zur förderung von osteogenese
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
CN101712722A
(zh)
|
2000-12-07 |
2010-05-26 |
伊莱利利公司 |
Glp-1融合蛋白
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
WO2002068579A2
(en)
|
2001-01-10 |
2002-09-06 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
US20020183276A1
(en)
|
2001-03-23 |
2002-12-05 |
Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
US7888372B2
(en)
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
US6808905B2
(en)
|
2001-05-14 |
2004-10-26 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
JP3935487B2
(ja)
|
2001-07-16 |
2007-06-20 |
フーベルト・ケスター |
捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
CA2469972A1
(en)
|
2001-12-20 |
2003-07-03 |
Phenogene Therapeutiques Inc. |
Bone polypeptide-1
|
EP1463751B1
(en)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
US20030158132A1
(en)
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
CA2478145A1
(en)
|
2002-03-06 |
2003-09-12 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
US20040077537A1
(en)
|
2002-03-18 |
2004-04-22 |
Schreiner George F. |
Method for treating congestive heart failure
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
CA2433479A1
(en)
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
CA2488348A1
(en)
|
2002-07-31 |
2004-02-05 |
Conjuchem Inc. |
Long lasting natriuretic peptide derivatives
|
WO2004022579A2
(en)
|
2002-09-06 |
2004-03-18 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
JP4610025B2
(ja)
|
2002-11-18 |
2011-01-12 |
シン.クス ファーマ、インコーポレイテッド |
NT−proBNP検出用ポリクローナル・モノクローナル・エライサ検定法
|
ATE459370T1
(de)
|
2002-11-26 |
2010-03-15 |
Biocon Ltd |
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
US20060135480A1
(en)
|
2002-12-03 |
2006-06-22 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
US20060172929A1
(en)
|
2003-01-13 |
2006-08-03 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
WO2004074320A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
EP1616181B1
(en)
|
2003-04-17 |
2009-08-12 |
Vermillion, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
US20070041972A1
(en)
|
2003-05-30 |
2007-02-22 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
DE602004030342D1
(de)
|
2003-06-17 |
2011-01-13 |
Otago Innovation Ltd |
Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
|
ATE485303T1
(de)
|
2003-06-20 |
2010-11-15 |
Mayo Foundation |
Isoformen von gehirn-natriuretischem peptid
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
ES2438098T3
(es)
|
2003-11-13 |
2014-01-15 |
Hanmi Science Co., Ltd. |
Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
WO2005070446A1
(en)
|
2004-01-15 |
2005-08-04 |
Scios Inc. |
Method for treating cardiac remodeling following myocardial injury
|
AU2005207886A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
AU2005222397A1
(en)
|
2004-03-11 |
2005-09-22 |
Genentech, Inc. |
Process for producing polypeptides
|
US8815803B2
(en)
|
2004-03-31 |
2014-08-26 |
Kazuwa Nakao |
Method for increasing body height comprising systemic administration of CNP-53
|
EP1759710B1
(en)
|
2004-03-31 |
2014-05-07 |
Kazuwa Nakao |
Remedy or preventive for arthritis
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
EP1759001B1
(en)
|
2004-04-21 |
2011-04-13 |
Enobia Pharma Inc. |
Bone delivery conjugates and method of using same to target proteins to bone
|
WO2005105156A1
(en)
|
2004-05-04 |
2005-11-10 |
National University Of Singapore |
Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
|
MXPA06013029A
(es)
|
2004-05-10 |
2007-02-12 |
Novacea Inc |
Prevencion de la restenosis arterial con compuestos de vitamina d activos.
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
US7972593B2
(en)
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
US7863238B2
(en)
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
US20070081984A1
(en)
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
WO2006005140A2
(en)
|
2004-07-15 |
2006-01-19 |
The University Of Queensland |
Proteinaceous compounds and uses therefor
|
WO2006039480A2
(en)
|
2004-09-29 |
2006-04-13 |
The Burnham Institute For Medical Research |
Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
|
MX2007006524A
(es)
|
2004-12-01 |
2007-06-22 |
Genzyme Corp |
Metodos para el suministro dirigido de material genetico al higado.
|
EP2510942B1
(en)
|
2005-04-07 |
2015-09-02 |
Cardiorentis AG |
Use of natriuretic peptide for treating heart failure
|
AU2006239851B2
(en)
|
2005-04-26 |
2011-06-16 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
EP1933863A4
(en)
|
2005-09-06 |
2010-06-09 |
Zelos Therapeutics Inc |
PARATHYROIDIAN HORMONE ANALOGS AND METHODS USING SAME
|
US7803901B2
(en)
|
2005-09-16 |
2010-09-28 |
Mayo Foundation For Medical Education And Research |
Polypeptides with natriuresis activity
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
JP5576610B2
(ja)
|
2006-02-20 |
2014-08-20 |
フィロジカ リミテッド |
ペプチド構造のライブラリーの構築およびスクリーニング方法
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
JP2010501026A
(ja)
|
2006-06-30 |
2010-01-14 |
インターフェース バイオロジクス,インコーポレーテッド |
生体応答性ポリマー
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
WO2008021872A1
(en)
|
2006-08-08 |
2008-02-21 |
Mayo Foundation For Medical Education And Research |
Diuretic and natriuretic polypeptides
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
CA2662453A1
(en)
|
2006-09-08 |
2008-03-13 |
Mayo Foundation For Medical Education And Research |
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
|
US7834164B2
(en)
|
2006-10-25 |
2010-11-16 |
Amgen Inc. |
DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression
|
US20100168443A1
(en)
|
2006-11-02 |
2010-07-01 |
University Of Virginia Patent Foundation |
Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
|
CN103961686A
(zh)
|
2006-11-16 |
2014-08-06 |
凯制药公司 |
用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
EP2118665B1
(en)
|
2007-03-12 |
2012-04-18 |
Biomedica Medizinprodukte GmbH & Co KG |
Diagnosis of septic complications
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
CA2687001C
(en)
*
|
2007-05-11 |
2019-02-12 |
Enobia Pharma Inc. |
Bone targeted alkaline phosphatase, kits and methods of use thereof
|
AU2008254951A1
(en)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
|
CA2689492A1
(en)
|
2007-06-06 |
2008-12-18 |
Boehringer Ingelheim International Gmbh |
Natriuretic fusion proteins
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
WO2009006520A1
(en)
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
AU2008274845A1
(en)
|
2007-07-06 |
2009-01-15 |
Theratechnologies Inc. |
Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
|
AU2008279379B2
(en)
|
2007-07-20 |
2016-03-24 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
WO2009042294A2
(en)
|
2007-08-10 |
2009-04-02 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
CA2699215A1
(en)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
(d-leu7 ) -histrelin as a therapeutic agent
|
WO2009039990A2
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of icam peptide as a therapeutic agent
|
ES2575397T3
(es)
|
2007-09-11 |
2016-06-28 |
Cardiopep Pharma Gmbh |
Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
|
AU2008297893A1
(en)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a deslorelin and mastoparan as a therapeutic agent
|
WO2009040083A2
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
EP2187945A2
(en)
|
2007-09-11 |
2010-05-26 |
Mondobiotech Laboratories AG |
Use of a peptide as a therapeutic agent
|
US8357656B2
(en)
|
2007-09-15 |
2013-01-22 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-C agonists
|
TWI367213B
(en)
|
2007-11-21 |
2012-07-01 |
Biomarin Pharm Inc |
Variants of c-type natriuretic peptide
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
CA2698582C
(en)
|
2008-05-23 |
2016-09-13 |
Asubio Pharma Co., Ltd. |
Peptide having an extending action for half-life of object peptide in plasma
|
EP2303305A4
(en)
|
2008-06-06 |
2012-07-04 |
Mayo Foundation |
CHIMERIC NATRIURETIC POLYPEPTIDES AND METHODS FOR INHIBITING CARDIAC REMODELING
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
KR20220002710A
(ko)
|
2008-06-26 |
2022-01-06 |
악셀레론 파마 인코포레이티드 |
액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
US8741842B2
(en)
|
2008-07-02 |
2014-06-03 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides with unique pharmacologic profiles
|
BRPI0916326A2
(pt)
|
2008-07-23 |
2020-08-25 |
Hanmi Holdings Co., Ltd. |
complexo polipeptídico compreendendo polímero não-peptidil com três extremidades funcionais
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
WO2010048308A2
(en)
|
2008-10-24 |
2010-04-29 |
Deborah Dickey |
Natriuretic polypeptides
|
US8455438B2
(en)
|
2008-12-29 |
2013-06-04 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
WO2010082804A2
(en)
|
2009-01-19 |
2010-07-22 |
Hanmi Pharm. Co., Ltd. |
Method for producing physiologically active protein or peptide using immunoglobulin fragment
|
EP2413969A4
(en)
|
2009-03-30 |
2012-09-05 |
Boehringer Ingelheim Int |
FUSION PROTEINS WITH DOG FC ELEMENTS
|
US20120053123A1
(en)
|
2009-05-05 |
2012-03-01 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
PE20120792A1
(es)
|
2009-05-20 |
2012-07-27 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
US8685024B2
(en)
|
2010-04-14 |
2014-04-01 |
Arrowhead Medical Device Technologies, Llc |
Intramedullary fixation device and methods for bone fixation and stabilization
|
AU2011245005A1
(en)
|
2010-04-30 |
2012-11-22 |
Alexion Pharma Holding |
Methods, compositions, and kits for the treatment of matrix mineralization disorders
|
US9266939B2
(en)
|
2010-12-27 |
2016-02-23 |
Alexion Pharmaceuticals, Inc. |
Compositions comprising natriuretic peptides and methods of use thereof
|
WO2013058833A1
(en)
|
2011-10-19 |
2013-04-25 |
Enobia Canada Limited Partnership |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
EP2776129B2
(en)
|
2011-11-10 |
2020-06-17 |
Kai Pharmaceuticals, Inc. |
Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
EP2877247A1
(en)
|
2012-07-25 |
2015-06-03 |
Psioxus Therapeutics Limited |
Use of s-pindolol for treating cachexia and sarcopenia
|
WO2014186809A2
(en)
|
2013-05-17 |
2014-11-20 |
The Translational Genomics Research Institute |
A genetic test to predict patient response to bone morphogenetic protein in arthrodesis
|
EP3461891B1
(en)
|
2014-01-24 |
2020-07-01 |
AM-Pharma B.V. |
Downstream processing of an alkaline phosphatase
|
SG11201606060WA
(en)
|
2014-01-24 |
2016-08-30 |
Am Pharma Bv |
Chimeric alkaline phosphatase-like proteins
|
RS61443B1
(sr)
|
2014-06-09 |
2021-03-31 |
Ultragenyx Pharmaceutical Inc |
Efektivna i efikasna kontrola serumskog fosfata za optimalno formiranje kostiju
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
EP3207132B1
(en)
|
2014-10-15 |
2019-07-31 |
Alexion Pharmaceuticals, Inc. |
Methods of shifting an isoelectric profile of a protein product and uses thereof
|
CA2967851C
(en)
*
|
2014-12-05 |
2024-02-27 |
Alexion Pharmaceuticals, Inc. |
Treating seizure with recombinant alkaline phosphatase
|
AU2016211447B2
(en)
*
|
2015-01-28 |
2021-09-23 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
KR101867134B1
(ko)
|
2015-03-23 |
2018-06-12 |
한양대학교 산학협력단 |
포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
|
KR102644116B1
(ko)
|
2015-08-17 |
2024-03-05 |
알렉시온 파마슈티칼스, 인코포레이티드 |
알칼린 포스파타제의 제조
|
WO2017058822A1
(en)
|
2015-09-28 |
2017-04-06 |
Alexion Pharmaceuticals, Inc. |
Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
|
WO2017074466A1
(en)
|
2015-10-30 |
2017-05-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
WO2017171871A1
(en)
*
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
AU2017240238B2
(en)
|
2016-04-01 |
2024-06-20 |
Alexion Pharmaceuticals, Inc. |
Treating muscle weakness with alkaline phosphatases
|
US10898549B2
(en)
*
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
EP3474886B1
(en)
|
2016-06-27 |
2021-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children and adolescents
|
WO2018035420A1
(en)
|
2016-08-18 |
2018-02-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treating tracheobronchomalacia
|
WO2018164995A1
(en)
|
2017-03-09 |
2018-09-13 |
Alexion Pharmaceuticals, Inc . |
Glycoprotein manufacturing process
|